New data on TNBC treatment!

Triple-negative breast cancer presents unique challenges and an urgent need for effective, personalized therapies. Treating advanced TNBC requires a deep understanding of:

  • Biomarker testing
  • Immunotherapy
  • PARP inhibitors
  • Antibody-drug conjugates

Watch our free CME/CE webinar as we dive into recent advancements in TNBC treatment, presenting practical case studies and the latest data on managing treatment-related adverse events.

Free CME/CE credits available: 1.0 AMA, ANCC, or AAPA


Interesting and encouraging new data: The phase 3 SCENT-04/KEYNOTE-D19 trial of pembrolizumab in combination with sacitizumab in patients with previously untreated PD-L1–positive metastatic triple-negative breast cancer showed a statistically significant and clinically meaningful improvement in progression-free survival compared with standard-of-care chemotherapy plus pembrolizumab. 

Rita Nanda
Rita Nanda, MD

Director of Breast Oncology
Associate Professor of Medicine
University of Chicago